Top Markets
#1 Islamic Coin Islamic Coin +151.47%
#2 DOVU DOVU +49.95%
#3 Black Phoenix Black Phoenix +34.49%
#4 Velvet Velvet +32.46%
#5 Akedo Akedo +15.63%
#6 DoubleZero DoubleZero +13.65%
#7 HOME HOME +12.67%
#8 Cross Cross +12.27%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.90%
#10 Cap Cap +10.33%
Coin of the day
Islamic Coin Islamic Coin
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Rangering i aksjer #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Aksjekurs
$17.15
Sist synkronisert: 2026-08-03
Markedsverdi
$6.51M
Endring (1 dag)
9.80%
Endring (1 år)
289.77%
Land
US
Handel Galera Therapeutics, Inc. (GRTX)

Kategori

Healthcare
P/E-forhold for Galera Therapeutics, Inc. (GRTX)
P/E-forhold per August 2026 TTM: 0.05
Ifølge Galera Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0.05. Ved slutten av 2023 hadde selskapet en P/E på -0.11.
P/E-forholdshistorikk for Galera Therapeutics, Inc. fra 2017 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) 0.05 -139.54%
2024 -0.13 20.44%
2023 -0.11 -83.10%
2022 -0.65 -55.87%
2021 -1.47 -57.12%
2020 -3.43 -45.48%
2019 -6.29 -35.93%
2018 -9.81 -98.74%
2017 -775.87 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 54,468.48%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 60,491.83%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 37,446.11%
BE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.